Background and Purpose-Although recent trials have suggested that stenting is worse than medical therapy for patients with severe symptomatic intracranial atherosclerotic stenosis, it is not clear whether this conclusion applies to a subset of patients with hypoperfusion symptoms. To justify for a new trial in China, we performed a multicenter prospective registry study to evaluate the safety and efficacy of endovascular stenting within 30 days for patients with severe symptomatic intracranial atherosclerotic stenosis. Methods-Patients with symptomatic intracranial atherosclerotic stenosis caused by 70% to 99% stenosis combined with poor collaterals were enrolled. The patients were treated either with balloon-mounted stent or with balloon predilation plus self-expanding stent as determined by the operators following a guideline. The primary outcome within 30 days is stroke, transient ischemic attack, and death after stenting. The secondary outcome is successful revascularization. The baseline characteristics and outcomes of the 2 treatment groups were compared. Results-From September 2013 to January 2015, among 354 consecutive patients, 300 patients (aged 58.3±9.78 years) were recruited, including 159 patients treated with balloon-mounted stent and 141 patients with balloon plus self-expanding stent. The 30-day rate of stroke, transient ischemic attack, and death was 4.3%. Successful revascularization was 97.3%. Patients treated with balloon-mounted stent were older, less likely to have middle cerebral artery lesions, more likely to have vertebral artery lesions, more likely to have Mori A lesions, less likely to have Mori C lesions, and likely to have lower degree of residual stenosis than patients treated with balloon plus self-expanding stent. Conclusions-The short-term safety and efficacy of endovascular stenting for patients with severe symptomatic intracranial atherosclerotic stenosis in China is acceptable. Balloon-mounted stent may have lower degree of residual stenosis than self-expanding stent. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01968122.
A therosclerotic intracranial artery stenosis is an important cause of ischemic stroke. 1, 2 Although intracranial angioplasty and stenting showed initial promise for the treatment of severe symptomatic intracranial atherosclerotic stenosis (ICAS), 3 the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke (SAMMPRIS) trial revealed negative results for the endovascular approach, largely because of an unexpectedly high rate of stroke and death in 30 days among patients treated with the Gateway and Wingspan system (Boston Scientific, Natick, MA) than that of patients treated with aggressive medical therapy alone (14.7% versus 5.8%; P=0.002). 4 The recently published Vitesse Intracranial Stent Study for Ischemic Stroke Therapy (VISSIT) trial concurred with SAMMPRIS, showing a higher rate of the 30-day primary safety end point in patients treated with the Pharos Vitesse balloon-expandable neurovascular stent system (Codman Neurovascular, Raynham, MA) than that of patients treated with the medical therapy (24.1% versus 9.4%, P=0.05). 5 The latter study suggested that the high risk of endovascular therapy was not unique to a specific device.
These studies suggest that endovascular therapy should not be the primary treatment for the general patient population with symptomatic ICAS, but do not exclude the possibility that a subgroup of patient may benefit from this treatment more than those benefit from the medical therapy. For example, patients with hypoperfusion stroke secondary to ICAS may continue to have symptoms, despite double antiplatelet therapy, statins, and tight control of hypertension and diabetes mellitus. 6 In fact, aggressive antihypertensive therapy may aggravate the symptoms of hypoperfusion. 7 Endovascular therapy, which could correct the perfusion deficit, may thus result in symptomatic relief after the procedure. Although reperfusion hemorrhage is a concern in this patient population, it remains to be tested whether endovascular therapy will be better in these patients, who are likely to fail medical therapy. Previous studies have identified angiographic features associated with high risks for intracranial angioplasty and stenting. 8 Complications are likely to occur in lesions ≥15 mm in length or in target vessel ≤2.0 mm in diameter. Vessel tortuosity may increase the technical difficulty and time of the procedure thus raising the risks. Vessel segments with perforators, particularly in patients with symptoms related to ischemia in the perforator territories, carry a high risk of ischemic complication from compromised flow to the perforators. 9, 10 Patients with these risk features can be identified and excluded from endovascular therapy to improve the safety of the treatment.
Intracranial atherosclerosis is more common in the Chinese population than in the whites. 11 Patients often present with multiple episodes of transient ischemic attacks (TIAs) rather than strokes. 12 In addition, the patient population tends to be younger in China. 13 These differences may potentially alter the risk and benefit ratio of endovascular therapy for ICAS. Indeed, case series in China suggested lower risks of endovascular therapy for ICAS than those reported for SAMMPRIS and VISSIT 14, 15 In these studies, the Gateway balloon and Wingspan self-expanding stent and the Apollo balloon-mounted stent (MicroPort Neuro Tech, Shanghai, China) were used for endovascular treatment. In addition, after the SAMMPRIS, a 30-day composite stroke or death rate of 4.5% was reported in 156 patients enrolled in a prospective study using a tailored endovascular treatment in a high-volume center in China. 16 Nonetheless, the weight of these studies do not compare with that of randomized clinical trials. 17 A randomized clinical trial with careful selection of patients is thus warranted in the Chinese population such that these patients are not deprived of a potentially beneficial treatment.
In preparation of such a trial, we designed this multicenter prospective registry study to evaluate the safety and efficacy of endovascular stenting within 30 days for patients with severe symptomatic ICAS in China.
Methods

Overall Design
Details of the trial design were published elsewhere. 18 This study was a prospective single-arm registry study with 20 participating sites. Approval by each site's institutional review board or ethics committee was obtained. Written informed consent was obtained from the patient or his or her legally authorized representative. All reported end points were evaluated and confirmed by a central adjudication committee composed of designated neurologists, neurosurgeons, and radiologists, blinded to the treatment choices. An independent Data and Safety Monitoring Board oversaw the conduction, safety, and efficacy of the study.
Enrollment of Patients
Inclusion and exclusion criteria were established by the executive committee. Patients were aged 18 to 85 years and had a symptomatic ICAS of 70% to 99% with a lesion length of ≤15 mm and target vessel diameter of ≥2.0 mm in the intracranial internal carotid artery, middle cerebral artery, intracranial vertebral artery, or basilar artery. The measurements were made on digital subtraction angiography (DSA) using the warfarin-aspirin symptomatic intracranial disease method with normal distal vessels as the reference. 19 The symptoms could be TIA or stroke within the past 90 days but had to be attributable to hypoperfusion in the territory of the target lesion. Hemodynamic impairment in the territory of the culprit artery was determined on imaging within 2 weeks before the operation, using any one of the following methods: (1) A cerebral blood flow decrease of ≥30% when compared with the perfusion on the contralateral side for an anterior circulation lesion or the anterior circulation territory for a posterior circulation lesion on perfusion computer tomography (CT). (2) An American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology Collateral Flow Grading System score of <3 on DSA. 20 (3) Hemodynamic ischemic lesion by magnetic resonance imaging (MRI). (4) Hypoperfusion by single-photon emission CT. (5) A peak systolic velocity of ≥200 cm/s and ≤1 collateral vessel that could be insonated on transcranial Doppler examination. 21 In this study, the hemodynamic ischemic lesion on MRI is defined as small ischemic infarcts in a watershed distribution in the culprit vessel territory. 6 Lesions that could be entirely explained as an embolic phenomenon or lacunar infarcts were excluded from this category. The images were centrally reviewed by at least 2 physicians, who were allowed to resolve disagreement through discussion. The patients were excluded from the study if the raters could not agree on the classification.
Patients were excluded if they had acute infarcts within 3 weeks, severe vessel tortuosity precluding the deployment of endovascular devices as determined by the executive committee, nonatherosclerotic lesion confirmed by high-resolution MRI, embolic or perforator stroke based on MRI or CT, or baseline modified Rankin Scale score of >3. Only patients without risk factors for intracranial atherosclerosis, or patients with lesion suspected to be nonatheroclerotic by regular CT, MRI, or DSA, were subjected to high-resolution MRI. All clinical and imaging data were reviewed centrally by the executive committee to decide whether patient was eligible for enrollment.
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Device Selection
Operators were instructed to choose the devices based on the following guideline, taking into consideration their experience and preference as well to ultimately select what they thought were best suited for the patients ( Figure I in the online-only Data Supplement). For patients with smooth arterial access and Mori A lesion, 8 the Apollo balloonmounted stent was selected. For patients with tortuous arterial access, or Mori C lesion, or lesion with a significant mismatch in the diameter between the proximal and the distal segments, balloon predilation plus self-expanding stent (Gateway balloon plus Wingspan stent system [Stryker, Maple Grove, MN]) was preferred.
Periprocedural Management
The procedures were performed by experienced neurointerventionists at each participating site. Either general anesthesia or local anesthesia was chosen depending on the operators' experience and preference. Intravenous heparin was administered after the placement of vascular access using a bolus of 75 U/kg followed by half the dose 1 hour later. The guiding catheter was advanced into the cervical vertebral or internal carotid artery as high as the vessel tortuosity allowed. Perioperative systolic blood pressure was kept between 100 and 120 mm Hg. Noncontrast head CT was obtained to exclude potential hemorrhage after the procedure. All patients were given a weight-based dose of 0.4-to 0.6-mL Fraxiparine (Sanofi Winthrop Industry) every 12 hours subcutaneously for 3 days and monitored closely until discharge.
Aggressive Medical Treatment
All patients received aspirin (100 mg/d) and clopidogrel (75 mg/d) for >5 days before the operation or a loading dose of 300 mg clopidogrel if the procedure was considered urgent. They were maintained on aspirin (100 mg/d) plus clopidogrel (75 mg/d) for 90 days after stenting. Aggressive medical therapy was implemented to achieve the following goals: systolic blood pressure of <140 mm Hg (or <130 mm Hg in patients with diabetes mellitus), low-density lipoprotein of <70 mg/dL (1.81 mmol/L) or a decrease by 50%, smoking cessation, lifestyle modification for obesity and sedentary state.
Primary and Secondary Outcomes
The primary outcome within 30 days was any stroke (including ischemic or hemorrhagic stroke), TIA, and death after stenting. Ischemic stroke is defined as a new focal neurological deficit of sudden onset, lasting at least 24 hours, unassociated with hemorrhage on CT or MRI. Hemorrhagic stroke is defined as a new brain hemorrhage, involving parenchymal hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage, that is associated with a seizure or with symptoms or signs lasting 24 hours or longer. TIA is defined as a transient episode of neurological dysfunction caused by focal brain or retinal ischemia that lasts for at least 10 minutes but resolves within 24 hours regardless of diffusion-weighted imaging changes. The secondary outcomes were successful revascularization (residual stenosis <20%) and procedural complications, including groin hematoma, vessel dissection, stent migration, new vascular events during the procedure or gastrointestinal hemorrhage.
Follow-Up
Follow-up information on clinical outcomes were reviewed and collected by trained personnel who were blinded to treatment assignment on 30 days after procedure via face-to-face interview. If necessary, brain imaging studies including magnetic resonance angiography or CT angiography were obtained in patients with symptoms.
Statistical Analysis
The results were analyzed primarily based on the intention-to-treat analysis. Per-protocol analysis was performed as well. Continuous variables were presented as mean±SD or median with interquartile range, as appropriate. Categorical variables were presented as percentages. Student t test or the Mann-Whitney U test (when continuous variables had skewed distributions) was used to identify the difference in the continuous variables. The difference in each of the categorical variables between the 2 groups was tested with χ 2 or Fisher exact tests (when the expected cell frequency was <5). A 2-tailed P value <0.05 was considered statistically significant. All analyses were performed using the software SAS 9.2 (SAS Institute Inc, Cary, NC).
Results
Patient Characteristics
A total of 20 sites in China received internal review board/ ethics committee approval, and 15 sites enrolled at least 1 patient. From September 2013 to January 2015, among 354 screened patients, 300 patients (aged 58.3±9.78 years) were recruited (Figure) , including 159 patients treated with balloon-mounted stent and 141 patients with balloon plus selfexpanding stent. The data on study end points presented below are based on all adverse events as of March 1, 2015, when the last patient enrolled completed the 30-day evaluation. The baseline characteristics of all patients are presented in Table 1 . The most common risk factor was hypertension in 71.7% of all the patients. The main qualifying event was stroke in 54.3% of the patients. The hemodynamic impairment in the culprit territory was confirmed by CT perfusion in 156 (52.0%) patients, by DSA in 122 (40.6%) patients, and by MRI in 22 patients (7.3%). Hypoperfusion was all confirmed by DSA at 
Primary and Secondary Outcomes
The 30-day rate of primary outcome was 4.3% (13/300; Table 2 ). Ischemic stroke occurred in 7 patients (2.3%) and hemorrhagic stroke in 1 patient (0.3%), and all related to the target territory. TIA occurred in 5 patients (1.7%), and all related to the target territory. No nonterritory ischemic stroke or hemorrhagic stroke or death occurred.
Successful revascularization was 97.3% (Table 2) . Eight patients with >20% residual stenosis were considered to have unsuccessful revascularization. The mean residual stenosis was 8.5%. The other adverse effects included 5 patients with groin hematoma, 2 with upper respiratory tract infection, 1 patient with gastric hemorrhage, and 1 with angina pectoris. 11 .3±8.39%; P=0.000) than patients treated with balloon angioplasty plus self-expanding stent. The other baseline characteristics and study outcomes had no significant difference between the 2 groups of patients (Table 3) .
Comparison of 2 Types of Endovascular Treatment
Discussion
This study was the first multicenter, prospective, endovascular registry for symptomatic ICAS in China, also the largest worldwide registry using both balloon-mounted stent and self-expanding stent. The purpose of this study was to identify a subgroup of patients with severe symptomatic ICAS who could benefit from the intracranial stenting. This study differed from the Wingspan registries and the endovascular arm of SAMMPRIS and VISSIT trials in the following features. [3] [4] [5] First, the study was performed in an era when there were >1 device available for the treatment of intracranial stenosis, and when operators have gained substantial experiences using these devices. All the operators in this study have used these devices to treat intracranial atherosclerosis for >2 years and have learned from the early mistakes in their own practice and from the published literatures. Second, the operators were allowed to choose between 2 different stents based on vascular anatomy, lesion morphology, and their own judgment. The result of this study thus pertained to the stenting treatment rather than devices. Third, this study was limited to patients with hypoperfusion symptoms. Because of poor collaterals, these patients were highly likely to fail medical therapy and benefit from revascularization. 22, 23 These patients, who often presented with frequent or crescendo TIAs, constituted a high proportion of symptomatic ICAS in Asian countries, and thus a large number of patients in the world. As a result, the trial was rapidly completed, despite the use of stringent patient selection criteria. Although the result from this study might not be generalizable to symptomatic ICAS as a whole, there was a clinical need to investigate stenting in this selected group of patients. Fourth, in contrast to the undersizing and underinflation guideline of the previous studies, the operators in this study were instructed to obtain as good an anatomic result as safely possible using both types of stents. The Wingspan registry and the SAMMPRIS trial showed a high degree of residual stenosis and a high rate of restenosis, which could have contributed to the persistent high event rate in the endovascular arm of the SAMMPRIS study. The new aggressive angioplasty guideline resulted in much lower degree of residual stenosis than the previous studies, but yet did not increase the procedure complication rate. The lower residual stenosis could offer higher benefits in the long run. In contrast to the primary outcome of 14.7% and 24.1% within 30 days in the SAMMPRIS and VISSIT trials, 4,5 only 4.3% of patients had TIA or stroke in this study. Several factors may have contributed to the low event rates and high successful revascularization rate observed in this registry. First, unlike the SAMMPRIS and VISSIT trials, patients enrolled in this study were selected for hypoperfusion etiology, effectively excluding patients with perforator strokes. Perforator stroke is one of the most common complications of endovascular treatment for ICAS. 7 For example, patients with middle basilar artery stenosis and pontine infarct or distal M1 stenosis and basal ganglia infarcts are at high risks of periprocedural complications related to occlusion of perforators in these segments caused by dissection, device coverage, vessel straightening or kinking, and thromboembolism. These patients may be better treated with medical therapy to stabilize the atherosclerotic plaque and to prevent further progression of local disease. Although reperfusion hemorrhage is a concern in this population, we only observed one case with symptomatic intraparenchymal hemorrhage in this study, suggesting that this risk can be minimized with increased vigilance and tight blood pressure in the postoperative period.
Moreover, the time from qualifying event to stent (mean 21 days) is longer than that noted in the SAMMPRIS trial (median, 7 days) and VISSIT trial (median, 9 days), allowing for better medical preparation of patients for the procedure, such as stabilization of the atherosclerotic plaque, thus reducing the thromboembolic events in the periprocedural period. Patients in this study had lower level of low-density lipoprotein (mean, 89.2 mg/dL) than in the SAMMPRIS trial (mean, 96.3 mg/dL) and the VISSIT trial (mean 100.6 mg/dL) at the time of procedure, and fewer patients were loaded with clopidogrel than in SAMMPRIS trial. Low level of low-density lipoprotein has been associated with low perioperative complications in studies on carotid stenting. [24] [25] [26] Although this delayed enrollment could have excluded a small number of patients with recurrent symptoms despite medical therapy, these patients were probably not good candidates for intracranial stenting because of a high risk of hemorrhage from recent infarcts. Furthermore, the operators in this study had the choice of using either balloon-mounted stent or self-expanding stent to maximize success rate and minimize procedural complications. Both balloon-mounted and self-expanding stents have their pros and cons. For example, balloon-mounted stents are more rigid and difficult to navigate along tortuous vessels, whereas self-expanding stents have lower radial force, thus less apt at achieving good revascularization in calcified lesions. Different devices may be best suited for different vascular access and lesion morphology. The tailored endovascular treatment strategy used in this trial may thus contribute to a low complication rate at 30 days when compared with the SAMMPRIS and VISSIT trials when the operators were forced to use a single device. 16, 27 In this study, the demographic differences between the balloon-mounted stent and the self-expanding stent groups may be related to operator experience and expected time of the procedure. For elderly patients, or patients with intracranial vertebral artery stenosis, or patients with Mori A lesion, operators preferred balloon-mounted stent because of its features of rapid exchange and shorter procedure time. For patients with middle cerebral artery stenosis, or patients with Mori C lesion, more operators adopted to implant selfexpanding stent because of its characteristic of flexibility to facilitate navigation through tortuous vascular access. On the contrary, the higher successful revascularization and lower degree of residual stenosis may be attributed to the stronger radial strength features of balloon-mounted stent than those of self-expanding stent.
There were some limitations in this study. First, the patient population was different from that in the Wingspan registry and SAMMPRIS VISSIT trials, and thus direct comparison of the results was not possible. Second, only Asian patients were enrolled and the results could not be generalized to other ethnic groups. Third, we only examined the clinical outcome within 30 days. The long-term risks of ischemic stroke after intracranial stenting remained unknown. Fourth, the low complication rates from a registry might not hold true in a randomized clinical trial. The previous intracranial stenting registries showed good safety outcomes that were refuted by later randomized trials. Whether the results of this registry could stand the examination by a randomized trial remained to be seen.
Although the study does not have a medical therapy arm to compare with, the low complication rate justifies for a new randomized trial of intracranial angioplasty and stenting for symptomatic ICAS using these new patient selection criteria at least in the Chinese population. The rapid enrollment of patients in this study suggests that such a trial is feasible as well. 
